Compare HP Inc (HPQ) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HP Inc vs Illumina, Inc. — how do they compare? HP Inc trades at $30.16 (market cap $29.25B), while Illumina, Inc. trades at $277.61 (market cap $39.95B). The key difference: Illumina, Inc. is the larger of the two by market cap, and HP Inc pays a 3.7% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold HP Inc for 69 Days and Illumina, Inc. for 83 Days on average.
| HPQ | ILMN | |
|---|---|---|
Market Cap | $29.25B | $39.95B |
Volume | 10,025,806 | 3,169,503 |
Sector | Technology | Health |
52-Week High | $35.48 | $293.69 |
52-Week Low | $18.20 | $91.00 |
Typical Hold Time | 69 Days | 83 Days |
Enterprise Value | $35.42B | $41.31B |
Dividend Yield | 3.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPQ is trading at $30.37, down 5.8% over the past 24 hours, with a bullish technical signal from moving averages but neutral oscillators. The company reported revenue of $55.30 billion in 2025 and has beaten earnings estimates for the last three quarters. Recent news highlights HP's new product launches and a dividend payment scheduled for October 2026, though the stock faces pressure from a forecasted decline in PC sales for 2027.
The outlook for HPQ is mixed, with strong cash flow and consistent earnings beats providing support, but risks from a weakening PC market and high liabilities tempering upside. Analyst consensus is a hold with a price target of $25.75, suggesting cautious optimism amid industry headwinds. Investment opportunity lies in valuation metrics like a low P/E of 12.38, but execution risks remain key.
Illumina (ILMN) trades at $271.02, up 1.22% and near its 52-week high, reflecting strong momentum. The stock exhibits a bullish technical trend with recent earnings beats and a positive analyst consensus. Revenue for 2025 was $4.34B with net income of $850M, marking a significant profit margin recovery. Cash flow from operations remains robust at $1.08B, supporting financial stability. Inclusion in the S&P 500 and focus on AI-driven genomics growth are key catalysts.
Outlook is positive given earnings momentum and strategic initiatives, but risks include valuation premiums and competitive pressures. The stock offers growth exposure to genomic innovation, though investors should monitor execution on AI integration and margin sustainability. Analyst price targets suggest moderate upside from current levels, with consensus at $241.00.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
